Evaluating treatment effectiveness for liver cancer
Official title: Study on the Classification of Comprehensive Treatment Effect of Hepatocellular Carcinoma
Run by Second Affiliated Hospital, Zhejiang University, School of Medicine · NCT06542796 · Data updated 2026-11-12
This study is testing a new way to choose the best treatment for advanced liver cancer by looking at patient data and specific markers to see if it can improve outcomes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Second Affiliated Hospital, Zhejiang University, School of Medicine Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Hangzhou, Zhejiang) |
| Status | Recruiting |
| Started | September 1, 2024 |
| Main results expected | March 31, 2027 |
| Study ends | May 1, 2027 |
| Registry record updated | February 10, 2025 |
| Trial ID | NCT06542796 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients diagnosed with advanced hepatocellular carcinoma.
✕Probably not a fit
Patients with severe comorbidities, a history of other malignancies, or those who have received prior anti-tumor treatments may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the effectiveness of comprehensive treatment for hepatocellular carcinoma (HCC) by analyzing patient data from the Second Affiliated Hospital of Zhejiang University. It focuses on identifying risk factors that influence treatment sensitivity, utilizing PD-L1 expression levels and the morphology of tertiary lymphoid structures to develop an efficacy evaluation model. A randomized controlled trial will then be conducted to validate this model and its practical application in selecting optimal treatment plans for patients with advanced liver cancer.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for patients with advanced liver cancer.
How similar studies have gone: Other studies have shown promising results with immunotherapy combined with targeted therapy in treating unresectable hepatocellular carcinoma, indicating potential success for this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with advanced hepatocellular carcinoma Exclusion Criteria: * Have comorbidities of severe diabetes, heart failure, liver and/or kidney failure * Have a history of schizophrenia * Have a history of other malignant tumors or metastatic liver tumors discovered after surgery * Received anti-tumor drugs for other diseases * Special groups such as pregnant and lactating women.
Where it's running
-
2ndAffiliated Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
HAIC plus iparomlimab or tuvonralimab with bevacizumab, followed by SBRT for advanced liver cancer with portal vein involvement or limited metastases
This trial will test whether giving hepatic artery infusion chemotherapy with an immune checkpoint antibody (iparomlimab or tuvonralimab) plus bevacizumab, followed by focused stereotactic radiation, helps people with advanced hepatocellular carcinoma that involves the portal vein or has a small number of metastases.
-
Evaluating immunotherapy for liver cancer in Chinese patients
This study is testing how well immunotherapy treatments work for Chinese patients with liver cancer to see if they are safe and effective in real-life situations.
-
Combining camrelizumab and apatinib with TACE for liver cancer treatment
This study is testing if combining two medications with a liver cancer treatment before surgery can help people with liver cancer live longer and have fewer problems after surgery.
-
Immunotherapy using GPC3-targeted CAR-T cells for liver cancer
This study is testing a new treatment using specially modified immune cells to see if they can help people with advanced liver cancer that has a specific protein called GPC3.
-
MRD-guided postoperative monitoring and adaptive treatment for resectable NSCLC
This study tests a personalized follow-up and treatment plan using ctDNA MRD testing and pathology to guide adjuvant therapy after surgery for stage IB-IIIA NSCLC treated with neoadjuvant immunotherapy.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.